Lumicell is a biotechnology company based in Wellesley, United States, focused on developing and marketing image-guided cancer surgery solutions. Their core mission is to enhance the precision of cancer surgeries by providing innovative imaging technologies that help surgeons detect and remove residual cancerous tissue. The company's flagship product, LUMISIGHT™, is designed to illuminate cancerous tissues during breast-conserving surgeries, aiming to improve surgical outcomes and reduce the need for follow-up procedures.
Lumicell has achieved significant milestones, including historic FDA approval for its cutting-edge imaging platform. The company has also received a positive recommendation from an FDA advisory committee regarding the benefit-risk profile of LUMISIGHT™. Lumicell regularly presents its research and advancements at prominent industry events such as the Society of Surgical Oncology Annual Meeting, underscoring its commitment to advancing fluorescence-guided surgery.
